The efficacy and safety of hyoscyamine, dicyclomine, and desipramine in the treatment of irritable pouch syndrome– a retrospective cohort study
Clicks: 1
ID: 317989
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #31 of 38 articles by views in Crohn s & Colitis 360
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Patients with ileal pouch–anal anastomosis (IPAA) frequently experience high bowel frequency and abdominal pain that are disproportionate to endoscopic inflammation, a condition often termed irritable pouch syndrome. Although antispasmodic agents and neuromodulators are widely used in irritable bowel syndrome, real-world data supporting their effectiveness and durability in patients with pouches remain limited. Methods We performed a retrospective cohort study of IPAA patients followed at pouch clinic between 2014 and 2025. Patients treated with hyoscyamine extended release (ER), dicyclomine, or desipramine for high bowel frequency or abdominal pain were included. Patients could receive multiple therapies sequentially over time. Clinical response was determined by physician-documented symptom improvement. Treatment persistence was assessed using electronic medical record prescription data. Results Among 219 eligible patients, 329 treatment courses were analyzed: 143 hyoscyamine ER, 80 dicyclomine, and 106 desipramine. In patients with high bowel frequency, 235 treatment courses resulted in clinical improvement in 68.5% of patients receiving hyoscyamine ER, 65.0% receiving dicyclomine, and 63.5% receiving desipramine. For abdominal pain (94 treatment courses), improvement for hyoscyamine ER, dicyclomine, and desipramine was observed in 61.5%, 68.3%, and 76.2% of courses, respectively. Approximately 60% of treatment courses persisted beyond one year. Long-term persistence (≥3 years) was highest with dicyclomine (48.7%), followed by desipramine (38.7%) and hyoscyamine ER (37.8%). Adverse events were infrequent and consistent with known safety profiles. Conclusions Antispasmodic agents and low-dose neuromodulators are associated with meaningful symptom improvement in patients with irritable pouch syndrome, supporting their role as adjunctive therapies for pouch-related functional symptoms.
| Reference Key |
openalex_W7165360728
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Hayden Vaughn, Mille D Long, Edward L. Barnes, Hans Herfarth |
| Journal | Crohn s & Colitis 360 |
| Year | 2026 |
| DOI |
10.1093/crocol/otag063
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.